C81.09
Nodular lymphocyte predominant Hodgkin lymphoma, extranodal and solid organ sites
Clinical Classification Guidelines
Medical Intelligence & Overview
Nodular lymphocyte predominant Hodgkin lymphoma (NLPHL) is a rare type of Hodgkin lymphoma, which is a cancer originating in the lymphatic system. The code C81.09 indicates this lymphoma affecting extranodal (outside the lymph nodes) and solid organ sites. Unlike classical Hodgkin lymphoma, NLPHL features distinct cell types and often follows a different clinical course, making it important to understand its characteristics, causes, symptoms, and treatment options.
Causes & Symptoms
Clinical Causes: Genetic predisposition: Family history of lymphoma or other cancers may increase risk. Immune system compromise: Conditions or therapies that weaken the immune system can potentially promote lymphoma development. Environmental exposures: Certain chemicals or prolonged exposure to toxins have been examined as possible contributors, though no definitive link has been established. Viral infections: Some associations with viruses, such as Epstein-Barr virus (EBV), have been observed in other types of Hodgkin lymphoma, but their role in NLPHL is less clear.
Key Symptoms: Painless swelling of lymph nodes, often in the neck, underarm, or groin. Fatigue and weakness that persists beyond usual tiredness. Unexplained fever that may fluctuate. Night sweats, frequently severe enough to disrupt sleep. Unintentional weight loss over several weeks or months. Itching that does not seem to relate to skin conditions. Symptoms related to affected extranodal or solid organ sites, such as abdominal pain or discomfort if the gastrointestinal tract is involved.
Diagnostic & Treatment
Diagnosis Path: Physical examination: Checking for swollen lymph nodes and assessing overall health. Imaging tests: CT scans, PET scans, or MRI to identify the extent and location of lymphoma. Lymph node biopsy: Removal of tissue for microscopic examination to confirm the diagnosis and distinguish NLPHL from other lymphomas. Immunohistochemistry: Laboratory tests to analyze cell markers, which helps confirm NLPHL's unique cell type. Blood tests: To evaluate overall health and organ function.
Treatment Protocols: Radiation therapy: Often used for localized disease to destroy cancer cells in specific areas. Chemotherapy: Systemic treatment to target cancer cells throughout the body, typically using drugs like ABVD or similar regimens. Immunotherapy: Emerging therapies involving monoclonal antibodies or immune-modulating agents are being explored. Watchful waiting: In some cases with indolent or asymptomatic disease, careful monitoring may be recommended before initiating treatment. Stem cell transplantation: Considered in advanced or relapsed cases when other therapies are not effective.
Clinical Advice & FAQs
Billing Guidance
Is C81.09 a billable ICD-10 code?
Yes, C81.09 is a specific, billable code that can be used to indicate a diagnosis for reimbursement purposes.
Documentation
How do I report C81.09?
Clinical documentation must specify the nature of Nodular lymphocyte predominant Hodgkin lymphoma, extranodal and solid organ sites and any associated comorbidities for accurate reporting.
Cite this Clinical Reference